Approaches for targeting cancer stem cells drug resistance

被引:27
作者
Rosa, Roberta [1 ]
D'Amato, Valentina [1 ]
De Placido, Sabino [1 ]
Bianco, Roberto [1 ]
机构
[1] Univ Napoli Federico II, Dipartimento Med Clin & Chirurg, Via Pansini 5, I-80131 Naples, Italy
关键词
Cancer stem cells; resistance; stemness; EMT; immune evasion; EPITHELIAL-MESENCHYMAL TRANSITION; FOCAL ADHESION KINASE; PROSTATE-CANCER; OVARIAN-CANCER; LUNG-CANCER; PHASE-II; PI3K/AKT/MTOR PATHWAY; DOCETAXEL RESISTANCE; MYELOID-LEUKEMIA; IMMUNE-RESPONSES;
D O I
10.1080/17460441.2016.1243525
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Several reports have suggested that a population of undifferentiated cells known as cancer stem cells (CSCs), is responsible for cancer formation and maintenance. In the last decade, the presence of CSCs in solid cancers have been reported. Areas covered: This review summarizes the main approaches for targeting CSCs drug resistance. It is indeed known that CSCs may contribute to resistance to conventional chemotherapy, radiotherapy and targeted agents. Among the mechanisms by which CSCs escape anticancer therapies, removal of therapeutic agents by drug efflux pumps, enhanced DNA damage repair, activation of mitogenic/anti-apoptotic pathways; the main features of CSCs, stemness and EMT, are involved, as well as the capability to evade immune response. Expert opinion: Different approaches are suitable to target CSCs mediated drug resistance. Some of them are currently under clinical evaluation in different cancer types. A better understanding of CSC biology, as well as more accurate study design, may maximize the therapeutic effects of these agents. In this respect, it is important to establish: (i) which molecules should be targeted; (ii) what drug combinations may be suitable; (iii) which patient settings will CSC targeting offer the highest clinical benefit; and (iv) how to integrate therapeutic approaches targeting CSCs with standard cancer therapy.
引用
收藏
页码:1201 / 1212
页数:12
相关论文
共 118 条
[81]  
Sanborn RE, 2013, J CLIN ONCOL, V31, DOI [10.1200/JCO.2013.49.0219, DOI 10.1200/JCO.2013.49.0219]
[82]   Emerging role of nanog in tumorigenesis and cancer stem cells [J].
Santaliz-Ruiz, Luis E. I. V. ;
Xie, Xiujie ;
Old, Matthew ;
Teknos, Theodoros N. ;
Pan, Quintin .
INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (12) :2741-2748
[83]   TGF-β/TGF-β receptor system and its role in physiological and pathological conditions [J].
Santibanez, Juan F. ;
Quintanilla, Miguel ;
Bernabeu, Carmelo .
CLINICAL SCIENCE, 2011, 121 (5-6) :233-251
[84]   CD133+Cancer Stem-like Cells in Small Cell Lung Cancer Are Highly Tumorigenic and Chemoresistant but Sensitive to a Novel Neuropeptide Antagonist [J].
Sarvi, Sana ;
Mackinnon, Alison C. ;
Avlonitis, Nicolaos ;
Bradley, Mark ;
Rintoul, Robert C. ;
Rassl, Doris M. ;
Wang, Wei ;
Forbes, Stuart J. ;
Gregory, Christopher D. ;
Sethi, Tariq .
CANCER RESEARCH, 2014, 74 (05) :1554-1565
[85]   Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters [J].
Saxena, M. ;
Stephens, M. A. ;
Pathak, H. ;
Rangarajan, A. .
CELL DEATH & DISEASE, 2011, 2 :e179-e179
[86]   Epitope landscape in breast and colorectal cancer [J].
Segal, Neil H. ;
Parsons, D. Williams ;
Peggs, Karl S. ;
Velcutlescu, Victor ;
Kinzler, Ken W. ;
Vogelstein, Bert ;
Allison, James P. .
CANCER RESEARCH, 2008, 68 (03) :889-892
[87]  
Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713
[88]   Filtering promiscuous compounds in early drug discovery: is it a good idea? [J].
Senger, Mario R. ;
Fraga, Carlos A. M. ;
Dantas, Rafael F. ;
Silva, Floriano P., Jr. .
DRUG DISCOVERY TODAY, 2016, 21 (06) :868-872
[89]   EGFR Inhibition Abrogates Leiomyosarcoma Cell Chemoresistance through Inactivation of Survival Pathways and Impairment of CSC Potential [J].
Sette, Giovanni ;
Salvati, Valentina ;
Memeo, Lorenzo ;
Fecchi, Katia ;
Colarossi, Cristina ;
Di Matteo, Paola ;
Signore, Michele ;
Biffoni, Mauro ;
D'Andrea, Vito ;
De Antoni, Enrico ;
Canzonieri, Vincenzo ;
De Maria, Ruggero ;
Eramo, Adriana .
PLOS ONE, 2012, 7 (10)
[90]   The LKB1-AMPK pathway: metabolism and growth control in tumour suppression [J].
Shackelford, David B. ;
Shaw, Reuben J. .
NATURE REVIEWS CANCER, 2009, 9 (08) :563-575